Axsome Malta v. Alkem Labs: Solriamfetol Patent Dispute Dismissed After 99 Days
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Axsome Malta, Ltd. v. Alkem Laboratories, Ltd. |
| Case Number | 2:25-cv-17395 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Nov 2025 – Feb 2026 99 days |
| Outcome | Dismissed Without Prejudice |
| Patents at Issue | |
| Accused Products | Samsung Galaxy S Series Smartphones |
Case Overview
The Parties
⚖️ Plaintiff
An affiliate of Axsome Therapeutics, Inc., a specialty pharmaceutical company focused on CNS disorders. Axsome holds branded rights to Sunosi® (solriamfetol).
🛡️ Defendant
A multinational generics manufacturer headquartered in India, with significant U.S. market presence. Alkem’s ANDA filing for generic solriamfetol triggered this infringement action.
Patents at Issue
This ANDA litigation involved two U.S. patents protecting Sunosi® (solriamfetol) — a wakefulness-promoting agent. Both patents are relatively recently issued, suggesting they are continuation or secondary patents layered onto the core exclusivity framework.
- • US 12,384,743 B2 — Related to formulation and/or method-of-use protections for solriamfetol.
- • US 12,390,419 B2 — Related to formulation and/or method-of-use protections for solriamfetol.
Developing a generic pharmaceutical product?
Check if your product might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case was dismissed without prejudice and without costs or attorneys’ fees to either party by stipulation under FRCP 41(a)(1)(A)(ii), just 99 days after filing. No damages were awarded, and no injunctive relief was granted or denied on the merits. Specific settlement terms, if any, were not disclosed in the public record.
Key Legal Issues
The swift, pre-merits resolution highlights the increasing role of early-stage negotiated settlements in pharmaceutical patent disputes. The dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii) means no judicial findings were made on infringement or validity, but it preserves Axsome’s right to reassert claims if agreements are breached. This outcome is common in Hatch-Waxman litigation, often reflecting confidential licensing or market entry date agreements, and underscores the strategic value of later-filed continuation patents.
Freedom to Operate (FTO) Analysis
This swift dismissal highlights unique FTO considerations in pharmaceutical ANDA litigation.
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in the solriamfetol drug class
- See which companies are active in CNS drug patents
- Understand ANDA litigation patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Generic Solriamfetol ANDA Filings
2 Patents Asserted
Covering solriamfetol formulation/method
Early Dismissal
Suggests negotiated outcome
✅ Key Takeaways
Stipulated dismissals under FRCP 41(a)(1)(A)(ii) resolve ANDA cases without creating precedent — preserving strategic flexibility for both parties.
Search related case law →Court-retained jurisdiction provisions signal enforceable underlying agreements even where terms are undisclosed.
Explore precedents →Secondary/continuation pharmaceutical patents generate independent Hatch-Waxman litigation triggers.
Analyze patent families →Frequently Asked Questions
The case involved U.S. Patent Nos. 12,384,743 B2 and 12,390,419 B2, both relating to solriamfetol — the active ingredient in Sunosi® oral tablets.
The parties stipulated to dismissal under FRCP 41(a)(1)(A)(ii) by mutual agreement, without costs or fees. A without-prejudice dismissal preserves Axsome’s right to reassert claims if circumstances warrant.
A resolution in less than 100 days is notably fast for Hatch-Waxman litigation, which typically spans 18-30 months. This speed strongly suggests the parties reached an early, negotiated settlement, likely involving an agreed-upon market entry date for the generic, rather than pursuing a full trial.
Axsome’s active assertion of continuation patents signals continued enforcement activity. Remaining parallel defendants may face similar claims, and any merits rulings in those proceedings could shape the validity and infringement landscape for these patents. Companies should monitor these other actions closely.
Ready to Strengthen Your Pharmaceutical Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Case Lookup — U.S. District Court for the District of New Jersey, Case 2:25-cv-17395
- USPTO Patent Center — US12384743B2
- USPTO Patent Center — US12390419B2
- FDA Orange Book — Sunosi® (solriamfetol)
- Cornell Legal Information Institute — Federal Rule of Civil Procedure 41(a)(1)(A)(ii)
- PatSnap — IP Intelligence Solutions for the Pharmaceutical Industry
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.